EBioMedicine (Mar 2020)

Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis

  • Xin-Chun Zhao,
  • Gui-Zhen Wang,
  • Zhe-Sheng Wen,
  • Yong-Chun Zhou,
  • Qian Hu,
  • Bin Zhang,
  • Li-Wei Qu,
  • San-Hui Gao,
  • Jie Liu,
  • Liang Ma,
  • Yan-Fei Zhang,
  • Chen Zhang,
  • Hong Yu,
  • Da-Lin Zhang,
  • Min Wang,
  • Chang-Li Wang,
  • Yun-Chao Huang,
  • Zhi-hua Liu,
  • Yong Zhao,
  • Liang Chen,
  • Guang-Biao Zhou

Journal volume & issue
Vol. 53

Abstract

Read online

Background: How the oncoprotein epidermal growth factor receptor (EGFR) evades proteolytic degradation and accumulates in non-small cell lung cancer (NSCLC) remains unclear, and ubiquitin pathway genes (UPGs) that are critical to NSCLC needs to be systematically identified. Methods: A total of 696 UPGs (including E1, E2, E3, and deubiquitinases) were silenced by small interfering RNA (siRNA) library in NSCLC cells, the candidates were verified, and their significance was evaluated in patients with NSCLC. The effects of a candidate gene on EGFR were investigated in vitro and in vivo. Findings: We report 31 candidates that are required for cell proliferation, with the E2 ubiquitin conjugase CDC34 as the most significant one. CDC34 is elevated in tumor tissues in 76 of 114 (66.7%) NSCLCs and inversely associated with prognosis, is higher in smoker patients than nonsmoker patients, and is induced by tobacco carcinogens in normal human lung epithelial cells. Forced expression of CDC34 promotes, whereas knockdown of CDC34 inhibits, NSCLC cell proliferation in vitro and in vivo. CDC34 competes with c-Cbl to bind Y1045 to inhibit polyubiquitination and degradation of EGFR. In EGFR-L858R and EGFR-T790M/Del (exon 19)-driven lung tumor growth in mouse models, knockdown of CDC34 significantly inhibits tumor formation. Interpretation: These results demonstrate that an E2 enzyme is capable of competing with E3 ligase to stabilize substrates, and CDC34 represents an attractive therapeutic target for NSCLCs. Funding: National Key Research and Development Program of China, National Natural Science Foundation of China, and the CAMS Innovation Fund for Medical Sciences. Keywords: Lung cancer, Ubiquitin pathway genes, CDC34, EGFR, c-Cbl